

Phase II Trial of Biweekly Paclitaxel and Gemcitabine as Second-Line Chemotherapy for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

Takashi KOBAYASHI, Tomonobu KOIZUMI*, Masanori YASUO
Kenji TSUSHIMA, Hiroshi YAMAMOTO and Keishi KUBO

First Department of Internal Medicine, Shinshu University School of Medicine

A phase II study was conducted to evaluate the feasibility and efficacy of biweekly administration of paclitaxel and gemcitabine in patients with non-small cell lung cancer (NSCLC) who had been treated previously with platinum-based chemotherapy. Paclitaxel (150 mg/m²) and gemcitabine (1,000 mg/m²) were administered biweekly for at least 4 cycles. Thirty-one patients with a median age of 64 years (39–75 years) were enrolled in this study (stage IIIB/IV : 11/20, PS 0/1/2 : 13/16/2). Partial response was observed in 7 cases (23 %), and stable disease was seen in 18 cases (58 %). Median survival time was 8.8 months with a one-year survival rate of 41.9 %. Hematological toxicities were mild and neutropenia of grade 3 or above was observed in one patient (3 %). Non-hematological toxicities were also mild, including neurotoxicity (3 %). Biweekly paclitaxel and gemcitabine combination chemotherapy was effective and tolerated well as second-line therapy against NSCLC. *Shinshu Med J 59 : 411–418, 2011*

(Received for publication May 2, 2011 ; accepted in revised form August 8, 2011)

Key words : second-line chemotherapy, biweekly, platinum-resistant, non-small cell lung cancer, neurotoxicity

I Introduction

In recent years, the efficacy of second-line chemotherapy has been established in phase III clinical trials for patients with advanced non-small cell lung cancer (NSCLC)¹⁾. Two chemotherapeutic agents, docetaxel and pemetrexed, and the biological agent erlotinib are currently approved for clinical use in patients with advanced NSCLC^{2)–5)}. However, the improvements in survival after these therapies are modest and other novel agents have become available for patients with NSCLC over the past decade. Therefore, it is still important to conduct clinical trials to evaluate the activity of other agents as second-line treatment for NSCLC.

Among the agents useful for NSCLC, paclitaxel is the first clinically available taxane the cytotoxicity of which is derived from suppression of the functions of mitotic microtubules⁶⁾. Gemcitabine (2',2'-difluoro-2'-deoxycytidine) is also a novel pyrimidine nucleoside analog⁷⁾. Both agents have yielded response rates of 21 %–26 % in advanced NSCLC with only mild toxicities when used in single-agent regimens⁸⁾. Platinum in combination with paclitaxel or gemcitabine has been studied extensively and shown response rates in the 21 %–62 % range in first-line chemotherapy for NSCLC^{9)–12)}. However, little information is available regarding the activity and feasibility of paclitaxel plus gemcitabine when used as second-line chemotherapy for NSCLC. These agents appear promising due to their specific mechanism of action and favorable toxicity profiles^{13)–15)}.

Previously, we conducted a phase I study of a biweekly combination of paclitaxel and gem-

* Corresponding author : Tomonobu Koizumi
First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto-city, Nagano-prefecture 390-8621, Japan

citabine and the results indicated recommended doses of 150 mg/m² for paclitaxel and 1,000 mg/m² for gemcitabine¹⁶. The present study was performed to further evaluate the effectiveness and safety of biweekly administration of paclitaxel and gemcitabine as second-line therapy for patients with advanced NSCLC who had been unsuccessfully treated with platinum-based chemotherapy.

II Method and Subjects

A Patient eligibility

Patients with histologically or cytologically confirmed stage IIIB or IV NSCLC in whom first-line chemotherapy with a platinum-containing regimen had failed or who had relapsed were eligible for this study. Other criteria were as follows: 1) age \geq 20 and \leq 75 years; 2) Eastern Clinical Oncology Group (ECOG) performance status 0 to 2; 3) adequate bone marrow function (neutrophil count \geq $2 \times 10^3/\mu\text{L}$, hemoglobin \geq 10 g/dL, platelet count \geq $100 \times 10^3/\mu\text{L}$), normal hepatic function (total bilirubin level \leq $1.5 \times$ and AST \leq $2 \times$ the upper normal limits), and renal function (creatinine \leq 1.5 mg/dL, creatinine clearance \geq 60 mL/min). Individuals with peripheral neuropathy were excluded. Patients with a history of partial response after prior paclitaxel chemotherapy were permitted to participate in the present study. In addition, patients were excluded from the trial for any of the following reasons: 1) active infection; 2) severe heart disease; 3) past history of hypersensitivity to drugs; 4) pleural or pericardial effusion requiring drainage; 5) active brain metastasis; or 6) pregnancy. Patients with other concurrent active malignancy were also excluded. No other concomitant anticancer therapy or experimental drug administration of any type was permitted. Written informed consent was obtained from each enrolled patient. The study was undertaken in accordance with the Declaration of Helsinki.

B Pretreatment evaluation

Before enrollment in the present study, all patients underwent clinical and physical examination. General condition, medical history, perfor-

mance status, differential blood cell counts, routine laboratory tests, and urinalysis results were obtained before the study. Electrocardiography, chest radiography, chest computed tomography (CT), abdominal ultrasound and/or CT scan, and whole-brain CT scan or magnetic resonance imaging (MRI) and isotope bone scan were also performed in all cases.

C Toxicity and response evaluation

During the study period, complete differential blood cell counts were obtained weekly. Routine chemistry measurements were performed biweekly before chemotherapy. If necessary, additional examinations of blood samples were performed. Examination of chest CT was performed after four cycles of chemotherapy for detailed tumor measurements. Toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria Version 2¹⁷. Tumor assessment by chest CT was performed after four cycles of chemotherapy. Response Evaluation Criteria in Solid Tumors (RECIST) was used for evaluation of tumor response¹⁸. All responses were evaluated carefully and confirmed by independent verification. Toxicities were expressed at the highest grade during chemotherapy and the delivery and compliance of the treatment were evaluated for the first four cycles of paclitaxel/gemcitabine administration.

D Treatment delivery and dose reduction

On day 1 of each chemotherapy cycle, paclitaxel (150 mg/m²) was administered first as an intravenous infusion over 1 h followed by gemcitabine (1,000 mg/m²) intravenously over 30 min. Paclitaxel (Taxol) and gemcitabine (Gemzar) were diluted in 250 mL and 100 mL of normal saline, respectively. To avoid hypersensitivity reactions, the following standard premedication was administered: dexamethasone 20 mg intravenously (IV), diphenhydramine 50 mg IV, and cimetidine 150 mg IV. These drugs were administered 30 min prior to paclitaxel administration. Chemotherapy cycles were repeated every 2 weeks. Recombinant human G-CSF was not given prophylactically. Administration of subsequent chemotherapy was allowed when absolute

neutrophil and platelet counts were more than $1.5 \times 10^3/\mu\text{L}$ and $75 \times 10^3/\mu\text{L}$, respectively. If these variables did not return to adequate levels by a maximum of 2 weeks, doses of both agents were reduced by 20%. Similarly, the dose reduction was adjusted in cases showing chemotherapy-induced febrile neutropenia or grade 4 hematological toxicity lasting for 4 days. Patients with disease progression at any cycle of chemotherapy or presenting with grade 3 or 4 nonhematological toxicity and requiring hospitalization were withdrawn from the study.

E Statistics

The main endpoint of this study was the response rate. Secondary endpoints were toxicities and overall survival. Response and survival rates were both calculated on an intent-to-treat basis. Overall survival was calculated from the date of initiation of this regimen to death or date of last follow-up (cutoff date: 31 March 2008). The Kaplan-Meier method was used to determine the medians of the time-related parameters.

III Results

A Patient characteristics

A total of 31 patients were enrolled in the study between August 2000 and January 2006. The clinical characteristics of the patients are summarized in Table 1. The study population consisted of 23 men and 8 women, with a median age of 67 years (range 39-75 years). Of the 31 patients, 29 had a PS of 0 or 1, and 2 had a PS of 2. Adenocarcinoma histology was noted in 26 patients. Eleven patients had stage IIIB disease and the remaining 20 had stage IV disease. All patients had been previously treated with platinum-containing regimens as first-line chemotherapy; 26 received platinum compound plus docetaxel, and the remaining 5 patients had been treated with platinum compound plus paclitaxel.

B Treatment delivery

A total of 161 cycles of biweekly administration of paclitaxel and gemcitabine were performed with a median of 4 cycles (range 1-20). Treatment delivery was evaluated during the first four cycles of chemotherapy. A delay of one week until the next

cycle occurred because of neutropenia (3 cases), non-neutropenic infection or fever (3 cases), and other reasons unrelated to treatment (2 cases). Pulmonary toxicity developed after only one cycle in one patient and disease progression was observed after two cycles in one patient, and chemotherapy was subsequently discontinued. Dose modification of these agents was not performed. Thus, 111 cycles of chemotherapy received the intended first four cycles, resulting in a completion rate of 89.5% (111/124 cycles).

C Toxicity

Toxicities were assessed in all patients. Hematological toxicities were generally mild, as shown in Table 2. Grade 3 neutropenia occurred in only one patient (3%) and none developed neutropenic fever during the present chemotherapy regimen. Interestingly, there were no cases of severe thrombocytopenia or anemia during therapy. Nonhematological toxicities are summarized in Table 3. Grade 2 and 3 peripheral sensory neurotox-

Table 1 Patient characteristics

Characteristic	No.	%
Sex		
Male	23	74
Female	8	26
Age (years)		
Median	67	
Range	39-75	
Performance status		
PS0	13	42
PS1	16	52
PS2	2	6
Histology		
Adenoca.	26	84
Squamous cell ca.	2	6
Large cell ca.	3	10
Stage		
IIIb	11	35
IV	20	65
First line chemotherapy		
cisplatin+docetaxel	25	81
carboplatin+paclitaxel	3	10
nedaplatin+paclitaxel	2	6
carboplatin+docetaxel	1	3

Table 2 Hematological toxicities

Toxicity	Grade (No.)					Grade \geq 3 (%)
	0	1	2	3	4	
Leukopenia	21	7	3	0	0	0
Neutropenia	19	5	6	1	0	3
Thrombocytopenia	30	1	0	0	0	0
Anemia	24	4	3	0	0	0

Table 3 Non-hematological toxicities

Toxicity	Grade (No.)					Grade \geq 3 (%)
	0	1	2	3	4	
Nausea	19	10	2	0	0	0
Diarrhea	27	3	1	0	0	0
Constipation	28	3	0	0	0	0
Neuropathy	15	7	8	1	0	3
Myalgia	19	11	1	0	0	0
Eruption	27	2	2	0	0	0
Alopecia	11	10	10	0	0	0
Edema	31	0	0	0	0	0
Infection without neutropenia	28	1	1	1	0	3
Liver dysfunction	28	3	0	0	0	0
Renal dysfunction	31	0	0	0	0	0
Pneumonitis	30	0	0	0	1	3

icities were observed in 8 cases (28 %) and one case (3 %), respectively. One patient developed severe pulmonary toxicity after only one cycle of chemotherapy, which resulted in a fatal outcome. No patients showed an allergic reaction to therapy or developed edema during chemotherapy.

D Efficacy

All 31 patients were included in the analyses of tumor response and survival. Partial response was observed in 7 patients (23 %; 95 % confidence interval (CI) 9.6 %-41.1 %), and stable disease was seen in 18 patients (58 %) (Table 4). Among the 7 patients who responded to prior docetaxel plus platinum compound chemotherapy, one patient achieved a partial response (14 %) to the gemcitabine and paclitaxel regimen. On the other hand, among 19 patients who failed to respond to the docetaxel-containing chemotherapy regimen, 5 patients showed a partial response (26 %) to the gemcitabine and paclitaxel regimen. There were no significant differences in response rate related to previous

Table 4 Response rate

Overall response	30	No. (%)
Partial response (PR)	7 (23 %)	(95 %CI 9.6-41.1 %)
Stable disease (SD)	18 (58 %)	
Progressive disease (PD)	5 (16 %)	
Not evaluated	1	(only 1 cycle)

responses to docetaxel.

The overall survival curve is shown in Fig. 1. Median survival time was 8.8 months (95 %CI 4.9-15.0 months), and 1-year survival rate was 41.9 % (95 %CI 24.6 %-59.3 %).

IV Discussion

The results of the present study indicated that paclitaxel plus gemcitabine administered biweekly could be combined safely for treatment of patients with NSCLC who had relapsed after or were resistant to platinum-based chemotherapy. The response rate was 23 % and median survival time




Fig. 1 Overall survival when treated with paclitaxel and gemcitabine as second-line chemotherapy in patients with non-small cell lung cancer (n=31).

The median survival time was estimated as 8.8 months (95 %CI 4.9-15.0 months), and 1-year survival rate was 41.9 % (95 %CI 24.6 %-59.3 %).

was 8.8 months with a 1-year survival rate of 41.9 %, which were promising results as second-line chemotherapy. Furthermore, the toxicity profiles were also acceptable.

Several studies using a combination of paclitaxel and gemcitabine as second-line therapy in patients with NSCLC have been reported. Mori et al.¹⁹⁾ conducted weekly administration of paclitaxel (100 mg/m² on days 1 and 8) and gemcitabine (1,000 mg/m² on days 1 and 8) in patients with NSCLC and reported a response rate of 32.5 % and MST of 41.7 weeks. Androulakis²⁰⁾ also reported an overall response rate of 18 % and MST of 47 weeks. The dose settings were: paclitaxel, 175 mg/m² day 8; and gemcitabine, 900 mg/m² days 1 and 8. These findings were almost identical to our results obtained by biweekly administration of paclitaxel (150 mg/m²) and gemcitabine (1,000 mg/m²), although survival benefit was slightly lower in the present study¹⁹⁾⁻²¹⁾. To our knowledge, no clinical studies have shown the superiority of a doublet regimen over single-agent chemotherapy in second-line treatment of NSCLC. Gemcitabine in combina-

tion with docetaxel failed to show a survival benefit compared with docetaxel alone in patients with previously treated NSCLC. Several studies, including the present study, demonstrated that combined gemcitabine and paclitaxel in second-line chemotherapy provided a relatively high response rate compared with studies using docetaxel. Thus, paclitaxel plus gemcitabine is a potentially useful novel regimen, which should be examined in phase III clinical trials as second-line chemotherapy for patients with NSCLC.

In the initial planning stages of this study, there was no patient selection for previous agents in combination with platinum. However, all patients enrolled in the present study were treated with chemotherapy regimens that included taxanes. Little information is available regarding the influence of previous administration of docetaxel on subsequent paclitaxel activity in patients with NSCLC. The superior activity of docetaxel in second-line therapy is comparable to those of vinorelbine and ifosfamide⁴⁾. However, the response and survival benefit of subsequent docetaxel therapy were in-

dependent of the previous use of paclitaxel²²⁾. The current paclitaxel and gemcitabine therapy regimen showed a response rate of 23 % in patients treated previously with a docetaxel-containing regimen. In addition, the 26 % response rate of paclitaxel plus gemcitabine in patients who failed to respond to docetaxel-including chemotherapy regimens suggested partial non-cross-resistance between docetaxel and paclitaxel, gemcitabine, or the combination therapy. The present study suggested that paclitaxel is also promising as second-line therapy in patients with NSCLC previously treated with docetaxel.

In the present study, hematological toxicities were mild. In particular, thrombocytopenia was infrequent. Grade 3-4 thrombocytopenia was observed in 30 %-50.4 % of cases treated with a combination of platinum plus gemcitabine⁹⁾¹¹⁾¹²⁾. Isla et al.¹⁵⁾ performed a Phase II study of biweekly paclitaxel (150 mg/m²) and gemcitabine (2,000 mg/m²) as first-line chemotherapy against NSCLC and reported that no thrombocytopenia exceeding grade 3 was observed. Similar findings at a lower frequency of thrombocytopenia were observed in other studies using gemcitabine and paclitaxel¹⁴⁾²¹⁾. However, weekly administration of paclitaxel and gemcitabine showed an incidence rate of thrombocytopenia exceeding grade 3 of 12.5 %. Therefore, the administration of combined paclitaxel and gemcitabine every two weeks appeared to show a reduced rate of thrombocytopenia.

Neurotoxicity was seen frequently in cases treated with paclitaxel-containing regimens. In particular, cumulative peripheral neuropathy could be the

dose-limiting toxicity of paclitaxel. The neurotoxicity observed in the present study may have been due to paclitaxel or the previous use of docetaxel or paclitaxel. Although patients with preexisting neuropathy were excluded from the present study, the incidences of neurotoxicity exceeding grade 3 (3 %) were low and were similar to those in other reports²³⁾⁻²⁵⁾. As it has been demonstrated that gemcitabine combined with paclitaxel did not lead to worse neurotoxicity than that observed with paclitaxel as single therapy¹⁴⁾²⁶⁾, we believe that our data support this.

One patient in the present study showed severe pulmonary toxicity. It has been reported that gemcitabine combined with docetaxel increases the risk of pulmonary toxicity compared to docetaxel alone²⁷⁾. Based on reports in the literature, the rates of pulmonary toxicity in paclitaxel plus gemcitabine combination are low compared with those associated with docetaxel plus gemcitabine. Thus, it is unlikely that the combination of paclitaxel and gemcitabine could be associated with increased pulmonary toxicity. However, pulmonary adverse events should be noteworthy toxicities in any chemotherapy regimen.

In summary, a biweekly regimen of a combination of paclitaxel (150 mg/m²) and gemcitabine (1,000 mg/m²) was well tolerated and showed good activity as second-line therapy in patients with NSCLC who had relapsed after or developed resistance to platinum-based chemotherapy. The results of our trial suggest that this is a candidate regimen for second-line treatment in NSCLC with a well-tolerated schedule of administration.

References

- 1) Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F: Second-line treatment of advanced non-small cell lung cancer. *J Thorac Oncol* 3: 430-440, 2008
- 2) Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* 18: 2095-2103, 2000
- 3) Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,

- Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr : Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 22 : 1589-1597, 2004
- 4) Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L : Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. *J Clin Oncol* 18 : 2354-2362, 2000
 - 5) Shepherd FA, Rodrigues PJ, Ciuleanu T , Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L : Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 353 : 123-132, 2005
 - 6) Rowinsky EK, Donehower RC : The clinical pharmacology of paclitaxel (Taxol). *Semin Oncol* 20 : 16-25, 1993
 - 7) Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB : Evaluation of the antitumor activity of gemcitabine (2',2' -difluoro-2'-deoxycytidine). *Cancer Res* 50 : 4417-4422, 1990
 - 8) Bunn PA Jr, Kelly K : New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer : A review of the literature and future directions. *Clin Cancer Res* 4 : 1087-1100, 1998
 - 9) Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold Ch, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH : Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 18 : 122-130, 2000
 - 10) Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, Thomas M, Greco FA : One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer : results of a multicentre, phase II trial. *Eur J Cancer* 34 : 654-658, 1998
 - 11) Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwon S, Ozols RF : Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer : a phase II toxicity, response and survival analysis. *J Clin Oncol* 13 : 1860-1870, 1995
 - 12) Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH : Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 346 : 92-98, 2002
 - 13) Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJA, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ : Gemcitabine and paclitaxel : pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. *J Clin Oncol* 17 : 2190-2197, 1999
 - 14) Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA 3rd, Eckhardt SG, Stephens CD, Forral K, Nicol SJ, von Hoff DD : Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. *Ann Oncol* 9 : 733-738, 1998
 - 15) Isla D, Rosell R, Sanchez JJ, Carrato A, Felip E, Camps C, Artal A, Gonzalez-Larriba JL, Azagra P, Alberola V, Martin C, Massuti B : Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 19 : 1071-1077, 2001
 - 16) Koizumi T, Yoshiike F, Inou H, Hatayama O, Sasabayashi M, Tsushima K, Yamamoto H, Hayasaka M, Kubo K : Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *Med Oncol* 21 : 133-138, 2004
 - 17) National Cancer Institute : Common Toxicity Criteria (CTC) v2.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
 - 18) Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States,

- National Cancer Institute of Canada. *J Natl Cancer Inst* 92 : 205-216, 2000
- 19) Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T : Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. *Cancer Chemother Pharmacol* 60 : 189-195, 2007
 - 20) Androulakis N, Kouroussis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyianni A, Georgopoulou T, Dimopoulou I, Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D, Georgoulas V : Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy : a multicenter phase II study. *Ann Oncol* 9 : 1127-1130, 1998
 - 21) Iaffaioli RV, Tortoriello A, Gravina A, Facchini G, Turitto G, Elia S, Griffo S, Gentile M, Fraioli G, Frattolillo A, Muto P, Libutti M, De Marino V, Illiano A, Barbarisi A : Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer. *Lung Cancer* 30 : 203-210, 2000
 - 22) Ichikawa M, Suzuki R, Kataoka K, Noda Y, Shindoh J, Matsumoto S, Tanikawa Y, Suzuki K, Baba K, Shindo Y, Kondo M, Imaizumi K, Kume H, Hasegawa Y, Takagi K, Taniguchi H : Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin : A multi-center phase II study. *Lung Cancer* 69 : 319-322, 2010
 - 23) Greco FA, Thomas M, Hainsworth JD : One-hour paclitaxel infusions : review of safety and efficacy. *Cancer J Sci Am* 5 : 179-191, 1999
 - 24) Hainsworth JD, Greco FA : Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II comparing two schedules. *Cancer* 74 : 1377-1382, 1994
 - 25) Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H : Clinical phase I study with one-hour paclitaxel infusion. *Ann Oncol* 9 : 569-572, 1998
 - 26) De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A : Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in cheo-naïve patients with advanced non-small-cell lung cancer. *Ann Oncol* 11 : 821-827, 2000
 - 27) Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takada Y, Ando M, Shibata T, Saijo N : Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer : results of a Japan Clinical Oncology Group trial (JCOG0104). *Ann Oncol* 20 : 835-841, 2009

(2011. 5. 2 received ; 2011. 8. 8 accepted)